These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 27000717)
1. A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases. Ye L; Ye H; Zhou Q; Li Z; Lin Q; Tan L; Gao W; Fu Z; Zheng S; Chen R Int J Surg; 2016 May; 29():108-17. PubMed ID: 27000717 [TBL] [Abstract][Full Text] [Related]
2. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases. Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862 [TBL] [Abstract][Full Text] [Related]
3. A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. Ellison TA; Wolfgang CL; Shi C; Cameron JL; Murakami P; Mun LJ; Singhi AD; Cornish TC; Olino K; Meriden Z; Choti M; Diaz LA; Pawlik TM; Schulick RD; Hruban RH; Edil BH Ann Surg; 2014 Feb; 259(2):204-12. PubMed ID: 23673766 [TBL] [Abstract][Full Text] [Related]
4. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study. Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772 [TBL] [Abstract][Full Text] [Related]
5. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm. Mirkin KA; Hollenbeak CS; Wong J J Surg Res; 2017 May; 211():206-214. PubMed ID: 28501118 [TBL] [Abstract][Full Text] [Related]
6. A prognostic nomogram in patients with distant metastasis of pancreatic neuroendocrine tumors: a population-based study. Cai JS; Chen HY; Lu YF; Yu RS Future Oncol; 2020 Jan; 16(2):4369-4379. PubMed ID: 31802701 [No Abstract] [Full Text] [Related]
7. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Strosberg JR; Cheema A; Weber JM; Ghayouri M; Han G; Hodul PJ; Kvols LK Ann Surg; 2012 Aug; 256(2):321-5. PubMed ID: 22415420 [TBL] [Abstract][Full Text] [Related]
8. Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors: A Retrospective Nationwide Multicenter Study in South Korea. Cho JH; Ryu JK; Song SY; Hwang JH; Lee DK; Woo SM; Joo YE; Jeong S; Lee SO; Park BK; Cheon YK; Han J; Kim TN; Lee JK; Moon SH; Kim H; Park ET; Hwang JC; Kim TH; Jeon TJ; Cho CM; Choi HS; Lee WJ Pancreas; 2016 Aug; 45(7):941-6. PubMed ID: 26765964 [TBL] [Abstract][Full Text] [Related]
9. Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: possible indications for a multimodal approach. Bertani E; Fazio N; Botteri E; Chiappa A; Falconi M; Grana C; Bodei L; Papis D; Spada F; Bazolli B; Andreoni B Surgery; 2014 Apr; 155(4):607-14. PubMed ID: 24582492 [TBL] [Abstract][Full Text] [Related]
10. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection. Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559 [TBL] [Abstract][Full Text] [Related]
11. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations. Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286 [TBL] [Abstract][Full Text] [Related]
12. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study. Birnbaum DJ; Turrini O; Vigano L; Russolillo N; Autret A; Moutardier V; Capussotti L; Le Treut YP; Delpero JR; Hardwigsen J Ann Surg Oncol; 2015 Mar; 22(3):1000-7. PubMed ID: 25190116 [TBL] [Abstract][Full Text] [Related]
13. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification. Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Nomograms for Patients With NF-Pan-NET After Pancreatectomy: A Retrospective Analysis Based on SEER Database. Wang Y; Kong Y; Yang Q; Zhou D Cancer Rep (Hoboken); 2024 Sep; 7(9):e2165. PubMed ID: 39234666 [TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems. Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279 [TBL] [Abstract][Full Text] [Related]
16. Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors. Pulvirenti A; Javed AA; Landoni L; Jamieson NB; Chou JF; Miotto M; He J; Gonen M; Pea A; Tang LH; Nessi C; Cingarlini S; D'Angelica MI; Gill AJ; Kingham TP; Scarpa A; Weiss MJ; Balachandran VP; Samra JS; Cameron JL; Jarnagin WR; Salvia R; Wolfgang CL; Allen PJ; Bassiy C Ann Surg; 2021 Dec; 274(6):1051-1057. PubMed ID: 31567347 [TBL] [Abstract][Full Text] [Related]
17. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification. Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515 [TBL] [Abstract][Full Text] [Related]
18. Prognostic Nomograms to Predict Overall Survival and Cancer-Specific Survival of Patients With Pancreatic Neuroendocrine Tumors: A Population-Based Study. Song Z; Wang S; Wu Y; Zhang J; Liu S Pancreas; 2021 Mar; 50(3):414-422. PubMed ID: 33835974 [TBL] [Abstract][Full Text] [Related]
19. Neutrophil Extracellular Traps and Macrophage Extracellular Traps Predict Postoperative Recurrence in Resectable Nonfunctional Pancreatic Neuroendocrine Tumors. Xu SS; Li H; Li TJ; Li S; Xia HY; Long J; Wu CT; Wang WQ; Zhang WH; Gao HL; Han X; Ye LY; Lin X; Xu HX; Yu XJ; Liu L Front Immunol; 2021; 12():577517. PubMed ID: 34084158 [TBL] [Abstract][Full Text] [Related]
20. Grading Using Ki-67 Index and Mitotic Rate Increases the Prognostic Accuracy of Pancreatic Neuroendocrine Tumors. Philips P; Kooby DA; Maithel S; Merchant NB; Weber SM; Winslow ER; Ahmad S; Kim HJ; Scoggins CR; McMasters KM; Martin RCG Pancreas; 2018 Mar; 47(3):326-331. PubMed ID: 29351120 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]